These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7990207)

  • 1. Race and access to erythropoietin by patients on hemodialysis.
    Sadler JH
    JAMA; 1994 Dec; 272(23):1818-9. PubMed ID: 7990207
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients.
    Petronis KR; Carroll CE; Held PJ; Port FK
    JAMA; 1994 Jun; 271(22):1760-3. PubMed ID: 8196119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
    Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
    JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment modalities for ESRD patients. USRDS. United State Renal Data System.
    Am J Kidney Dis; 1997 Aug; 30(2 Suppl 1):S54-66. PubMed ID: 9259693
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant erythropoietin. The effect of the marketplace on socialized patient care.
    Besarab A; Erslev AJ
    ASAIO J; 1993; 39(2):85-6. PubMed ID: 8324265
    [No Abstract]   [Full Text] [Related]  

  • 6. Selected research topics.
    Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):96-104. PubMed ID: 1951363
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythropoietin & ESRD payments: a promising policy outcome?
    Roe W
    Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
    [No Abstract]   [Full Text] [Related]  

  • 8. A review of the first year of Medicare coverage of erythropoietin.
    Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
    Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant erythropoietin and Medicare payment.
    Sisk JE; Gianfrancesco FD; Coster JM
    JAMA; 1991 Jul; 266(2):247-52. PubMed ID: 2056627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 11. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of recombinant human erythropoietin on hemodynamics in chronic hemodialysis patients].
    Tomura S
    Nihon Rinsho; 1991 Dec; 49 Suppl():695-701. PubMed ID: 1808338
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group.
    Laupacis A
    Semin Nephrol; 1990 Mar; 10(2 Suppl 1):11-9. PubMed ID: 2192412
    [No Abstract]   [Full Text] [Related]  

  • 14. Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
    Coyne DW
    Nephrol News Issues; 2013 Feb; 27(2):16, 18, 20. PubMed ID: 23469454
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of recombinant human erythropoietin on reticulocyte age in hemodialysis patients.
    Zachée P; Van Hove L; Hauglustaine D; Veressen L; Boogaerts MA
    Nephron; 1992; 62(3):366-7. PubMed ID: 1436357
    [No Abstract]   [Full Text] [Related]  

  • 16. [Two new drugs. Recombinant "human" erythropoietin (EPO: Erypo, Recormon)].
    Verwiebe R
    Internist (Berl); 1992 Apr; 33(4):279-81. PubMed ID: 1612854
    [No Abstract]   [Full Text] [Related]  

  • 17. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kukhtevich AV
    Ter Arkh; 1995; 67(5):27-31. PubMed ID: 7638771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paying for expensive new technologies: Medicare's experiences with recombinant erythropoietin.
    Coster JM; Gianfrancesco F; Chuldzinski P
    Cancer Invest; 1991; 9(6):675-81. PubMed ID: 1747793
    [No Abstract]   [Full Text] [Related]  

  • 20. [Erythropoietin].
    Uhl D
    Med Monatsschr Pharm; 1990 May; 13(5):130-1. PubMed ID: 2192242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.